NXTC•globenewswire•
NextCure Provides Business Update
Summary
BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 23, 2026 by globenewswire